Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
01 Octubre 2024 - 3:05PM
Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable,
commercial-stage biotechnology company with clinical development
programs focusing on a variety of chronic organ diseases, today
announced that Han Ying, PhD, Chief Executive Officer, will be
presenting a company overview at the 8th Annual H.C. Wainwright
MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET
(11:30 AM PT).
The live webcast will be available on the Events
and Presentations page of Gyre’s website. A webcast replay will be
accessible following the live session.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company
headquartered in San Diego, CA, with a primary focus on the
development and commercialization of F351 (Hydronidone) for the
treatment of MASH-associated fibrosis in the U.S. Gyre’s
development strategy for F351 in MASH is based on the company’s
experience in MASH rodent model mechanistic studies and CHB-induced
liver fibrosis clinical studies. Gyre is also advancing a diverse
pipeline in the PRC through its indirect controlling interest in
Gyre Pharmaceuticals, including ETUARY therapeutic expansions,
F573, F528, and F230.
For Investors:Stephen
Jasperstephen@gilmartinir.com
Gyre Therapeutics (NASDAQ:GYRE)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Gyre Therapeutics (NASDAQ:GYRE)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024